McKesson Reports 8% Revenue Growth to $105.4 Billion, Net Income Decreases by 22%

McKesson Corporation reported a revenue increase of 8% for the three months ended June 30, 2026, reaching $105.4 billion compared to $97.8 billion in the same period last year. The company's gross profit also rose by 12% to $3.7 billion, driven primarily by growth in its North American Pharmaceutical segment, which saw higher volumes from institutional healthcare providers and retail national account customers. However, net income attributable to McKesson Corporation decreased by 22% to $614 million, resulting in diluted earnings per share of $5.15, down from $6.25 in the prior year.

The financial performance reflects significant operational changes, including a restructuring initiative that resulted in $136 million in charges for the quarter, compared to $47 million in the same period last year. This restructuring is part of a broader strategy to optimize operations and align with long-term goals, which includes headcount reductions and facility downsizing. The company also recorded a credit of $34 million related to its estimated liability for opioid-related claims, which contributed to the overall financial results.

In terms of strategic developments, McKesson completed a significant transaction on June 1, 2026, where Apollo Funds acquired a 13% minority interest in its Medical-Surgical Solutions business for approximately $1.25 billion. This move is part of McKesson's plan to separate this segment into an independent company. Additionally, the company has been active in the debt market, securing $3.2 billion through various credit agreements to support its operations and acquisitions.

Operationally, McKesson's North American Pharmaceutical segment generated $86.8 billion in revenue, a 5% increase from the previous year, while the Oncology & Multispecialty segment saw a notable 33% increase in revenue to $14.2 billion, driven by higher specialty pharmaceutical sales. The Prescription Technology Solutions segment also reported a 9% revenue increase, reflecting growing demand for its services. The company’s total assets increased to $88.3 billion as of June 30, 2026, up from $82.3 billion at the end of the previous fiscal year.

Looking ahead, McKesson anticipates continued growth driven by market demand and strategic initiatives. The company remains focused on enhancing operational efficiencies and expanding its service offerings across its segments. However, it also acknowledges potential risks related to regulatory changes and ongoing litigation, particularly concerning opioid-related claims, which could impact future financial performance.